Emerging scientific evidence suggests that two distinct neurological disorders, amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS), may share underlying biological features related to copper metabolism. A 2024 review in the journal International Journal of Molecular Sciences synthesized findings indicating that dysregulation of copper homeostasis is a common factor in both diseases.
Research points to a specific protein, metallothionein-3 (MT3), as being potentially crucial. Studies have shown that MT3, which binds copper and zinc in the brain, is significantly decreased in the spinal cords of ALS patients. Similar disruptions in metal-binding proteins and copper levels have been observed in models of MS, suggesting a shared pathway of neuronal vulnerability.
While ALS involves the progressive degeneration of motor neurons and MS is an autoimmune disease that attacks the central nervous system's myelin sheath, the copper link highlights a potential common thread in their pathology. Scientists theorize that improper copper handling could lead to increased oxidative stress and toxicity, contributing to damage in both conditions.
Experts caution that this represents a developing area of research and is not yet a diagnostic tool or treatment target. However, understanding these shared mechanisms could open new avenues for therapeutic strategies aimed at modulating metal metabolism in neurodegenerative and neuroinflammatory diseases.
